Abstract: BACKGROUND: Due to the lacking specificity of symptoms making a correct diagnosis can be a challenge in children with medulloblastoma. This can lead to prediagnostic symptomatic intervals (PSIs) of several weeks to months. It is unknown whether the length of the PSI is associated with an inferior survival outcome in this population. METHODS: To study the association of PSI with disease stage at diagnosis, tumour control and survival in children with medulloblastoma, prospectively collected data on PSI, clinical, and biological features were analysed in 224 patients diagnosed at the age of 3-18years and treated within the prospective randomised multicentre trial HIT'91. RESULTS: Patients with lower-stage disease tended towards a longer median PSI than those with higher-stage disease (M0 stage, 2.0months; M1 stage, 2.0months; M2/M3 stage, 1month; p=0.094. M0/1 stage versus M2/3 stage; p=0.025). The patient group with the longest PSI had the best survival outcome (PSI 4.0months: 10-year overall survival rate (OS), 71%; PSI <4.0months, 10-year OS, 61%; p=0.056). Age at diagnosis was positively correlated with PSI (p=0.027). No associations were found between PSI and sex histological subtype, presence of postoperative residual tumour, or c-myc and TrkC mRNA expression. CONCLUSION: Contrary to a common belief that a longer PSI may adversely affect prognosis, a longer PSI was associated with a trend towards lower metastatic stage and better survival probabilities. Nevertheless these findings do not obviate the importance of a timely diagnosis in paediatric patients with medulloblastoma. CONCLUSION: Contrary to a common belief that a longer PSI may adversely affect prognosis, a longer PSI was associated with a trend towards lower metastatic stage and better survival probabilities. Nevertheless these findings do not obviate the importance of a timely diagnosis in pediatric patients with medulloblastoma.
CONCLUSION: Contrary to a common belief that a longer PSI may adversely affect prognosis, a longer PSI was associated with a trend towards lower metastatic stage and better survival probabilities. Nevertheless these findings do not obviate the importance of a timely diagnosis in pediatric patients with medulloblastoma.
INTRODUCTION
Medulloblastoma is a primitive neuroectodermal tumor of the cerebellum with a tendency to metastasize by leptomeningeal spread. It is the most common malignant brain tumor in pediatric patients accounting for 20% of all central nervous system tumors. Advances in diagnostic, surgical, radiotherapeutic and chemotherapeutic methods have led to markedly improved survival outcome in the last decades.
However, a significant proportion of patients still succumb to their disease.
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Making a correct diagnosis can be a challenge due to often non-specific symptoms and signs which not only depend on the tumor itself, but also on the patient's age and developmental stage. 3 This can lead to prediagnostic symptomatic intervals (PSI) ('diagnostic time lags') in the range of several weeks to months. [4] [5] [6] [7] [8] [9] [10] [11] The assumption that a longer PSI may result in a more advanced disease stage and/or have an adverse impact on tumor control, survival and/or neurological/neuropsychological/quality of survival outcome may lead to selfreproaches from parents and physicians and can result in accusations of medical malpractice. [12] [13] [14] However, available information on the correctness of this assumption is insufficient, as studies on PSI in children with brain tumors suffer from low patient numbers, retrospective design, heterogeneity of patient, disease, and treatment characteristics, and lacking outcome data. [4] [5] [6] [7] [8] [9] [10] [11] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] To study the association of the PSI with disease stage at diagnosis as well as tumor control and survival outcome, we analyzed prospectively collected data on 224 homogeneously treated patients. 3. RESULTS
Patient and disease characteristics and presenting symptoms
Patient and disease characteristics of the 224 study patients are summarized in Table 1 . The most frequent presenting symptoms were headache, vomiting, ataxia, diplopia/squint, and vertigo/dizziness ( Table 2 ). Headache and vertigo/dizziness were more frequently recorded in older (≥7 year-old) children, whereas ataxia was more prevalent in younger (<7 year-old) children (p<0.05). No association was found between the frequency of any symptom and the metastatic stage. mRNA expression level had a trend towards a higher PSI (p=0.085), no association was found between PSI and TrkC mRNA level. Apart from vomiting, which was associated with a shorter PSI (p=0.028), no associations were found between PSI and other symptoms (Table 3 ).
Survival probabilities according to prediagnostic symptomatic interval and other clinical factors
Survival rates were slightly higher in the group with the longest PSI ( Table 4 , Figure   4 ). When the patient group with the longest PSI (4.0 -48.0 months) was compared to those with a shorter PSI (0 -3.9 months), 10-year PFS probabilities were 66 and 56%, respectively (p=0.202), and 10-year OS probabilities were 71% and 61%, respectively (p=0.056). When only patients with M0 were analyzed, a similar result was found. Survival probabilities according to other factors are summarized in Table   4 .
In a multivariable Cox-regression analysis, forward and backward stepwise selection both identified lower age at primary surgery, higher metastatic stage at diagnosis, and 'sandwich' therapy arm as independent risk factors for lower PFS and OS probabilities. Higher expression of c-myc mRNA and lower expression of TrkC mRNA were retained in the backward selection only. In accordance to univariable analysis, longer duration of PSI was not shown to be associated with adverse outcome.
DISCUSSION
Due to its rarity and the non-specificity of symptoms and signs, childhood cancer frequently poses a major diagnostic challenge. This often results in PSIs in the range of several weeks to months. 5-9, 11, 15, 28-30 Both the symptoms and the uncertainty of their origin can contribute to significant stress and suffering in patients and their parents/carers. 12 Patients and physicians often speculate on whether an earlier diagnosis would have led to a less advanced disease stage and ultimately to a better prognosis, and alleged delay in diagnosis is a frequent source of medical malpractice lawsuits. [13] [14] However, published data on the effect of the PSI on the outcome in children with brain tumors and specifically medulloblastomas are still limited and inconclusive.
To study the association of the PSI with disease stage at diagnosis, tumor control and survival outcome, we analyzed prospectively collected data on 224 welldocumented patients with medulloblastoma aged 3 -18 years at diagnosis treated within the multicenter trial HIT'91. 2 Median PSI of 2.0 months (range, 0.1 -48.0 months) as well as nature and prevalence of the presenting symptoms and signs were comparable to those in other series. 4-8, 11, 15, 18, 20, 23 Contrary to common belief that a longer PSI is associated with more extensive disease, we found that patients with metastatic disease at presentation had a shorter median PSI than those without As in some studies the presence of post-operative residual tumor is an independent risk factor for tumor progression and death in patients with non-metastatic disease, 31 we hypothesized that a longer PSI may lead to a compromised resectability in this patient group. However, we could not detect any difference in PSI between those patients with any residual tumor and those without. Setting the cut-off to a residual tumor size of 1.5 cm 2 yielded similar results.
These results may seem counterintuitive, as one might expect longer PSIs to be associated with inferior survival, possibly caused by a more advanced disease stage by the time of diagnosis and/or a lower rate of gross-total tumor resection achieved.
The association of a longer PSI with a lower metastatic stage and the trend towards a better progression-free and overall survival outcome are most probably explained by the biology of the disease. Medulloblastoma comprises a group of biologically highly heterogeneous diseases displaying a broad variability of clinical behavior. 27, [32] [33] [34] [35] Aggressive tumor growth may lead to more rapid clinical deterioration and hence to diagnosis within a shorter time period as compared to tumors with less aggressive growth characteristics. We could not find an association between PSI duration and histological subtype in our series, which however could be explained by the small patient number with non-classic histology. Apart from histology, other biologic markers are of known prognostic significance in medulloblastoma. 27, [36] [37] [38] When comparing the PSIs of those patients with high c-myc mRNA expression (a negative prognostic marker) to those with lower expression, we found a trend towards a shorter PSI in those patients with higher c-myc expression (p=0.073), supporting to a certain degree our hypothesis that a biologically more aggressive disease may translate into a shorter PSI. A corresponding trend could not be demonstrated for TrkC mRNA expression. As c-myc and N-myc DNA amplification 27 were only present in 5 patients each, we did not consider any corresponding analysis meaningful.
These results however do not disprove the hypothesis that tumor biology may explain these counterintuitive results, as our analyses were limited by relatively small patient numbers with non-classic histology or available tissue for molecular analyses, and furthermore, histological subtype and c-myc/TrkC mRNA expression levels constitute only a small part of biological markers related to aggressiveness of disease.
In our series older children and adolescents had longer PSIs than younger ones. This is in accordance with other studies of children with brain tumors or other neoplasms. is the first study evaluating the influence of biological markers on PSI in pediatric brain tumor patients. A limitation of our study is the lack of neurological, neuropsychological, and quality of life outcome information. One might for instance speculate that in a subgroup of patients with obstructive hydrocephalus a longer exposure to intracranial hypertension before diagnosis could lead to an adverse neuropsychological outcome. 40 As only recently medulloblastoma trials have started prospectively collecting neuropsychological and quality of life outcome data, such issues may be addressed in the future. A further limitation, which applies to all PSI studies, is the lack of an objective measure of the PSI duration. We believe that the judgment of the treating oncologist based on clinical history and examination(s), as used in our analysis, is the best estimate of the true PSI. We cannot exclude underor overestimations of the PSI in individual patients. However, the possibility of recall bias was minimized by the prospective nature of data collection, as the case report forms were completed at enrollment in the trial. Another limitation is the incomplete number of tumor samples available for expression analysis of c-myc and TrkC mRNA, and the lack of data on beta-catenin status, one of the best characterized biological prognostic factors in medulloblastoma. 38 Future trials incorporating tumor material collection for biological studies are warranted to further explore such correlations.
In conclusion, a longer PSI was associated with lower metastatic stage at presentation and a trend towards higher progression-free and overall survival 
Fisher's exact test (only for symptoms with a prevalence of ≥5%) NOS, not otherwise specified 
